Steroid hormone phospholipid composition and preparation method thereof

CN119053322APending Publication Date: 2024-11-29CHANGCHUN GENESCIENCE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035333.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-31
Filing Date
2023-09-15
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Steroid hormones such as progesterone have low oral bioavailability due to low solubility and low permeability. They require frequent injections and cause local muscle inflammatory reactions. There are obvious peaks and valleys in blood concentration, and patient compliance is low.

Method used

A composition of steroid hormones and phospholipids is used. The steroid hormones are mixed with phospholipids and cholesterol at a specific molar ratio to form liposomes, which are combined with a solvent to form a solid composition, which is prepared by freeze-drying and then reconstituted in an aqueous medium. Dissolves to achieve long-lasting release.

Benefits of technology

It improves the solubility and bioavailability of steroid hormones, reduces the frequency of injection, prolongs the efficacy, reduces adverse reactions, achieves a long-term and stable release effect of 5-30 days, and improves the patient's medication compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053322A_ABST
    Figure CN119053322A_ABST
Patent Text Reader

Abstract

The invention relates to a steroidal hormone phospholipid composition and a preparation method thereof, and the composition comprises steroidal hormone and phospholipid, and can further comprise cholesterol. The composition is prepared into freeze-dried powder which is easy to store, good in stability and convenient to use, and a redissolved preparation can maintain a long-acting stable release effect for 5-30 days in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

A steroid hormone phospholipid composition and preparation method thereof

[0001] This application claims priority from the following patent applications:

[0002] A prior application filed with the State Intellectual Property Office of China on September 16, 2022, with patent application number 202211132233.8 and titled “A steroid hormone phospholipid composition and its preparation method”;

[0003] A prior application filed with the State Intellectual Property Office of China on August 31, 2023, with patent application number 202311117793.0 and title “A steroid hormone phospholipid composition and its preparation method”;

[0004] The entire contents of said prior application are incorporated into the present application by reference. Technical Field

[0005] The present invention belongs to the field of pharmaceutical preparations, and in particular relates to a long-acting steroid hormone phospholipid composition suitable for industrialization and a preparation method thereof. Background Art

[0006] Phospholipids are substances with an amphiphilic structure with a hydrophilic head (phosphate group and quaternary ammonium salt) and a hydrophobic tail (long-chain hydrocarbon group), and they have good biocompatibility. Cholesterol has a cyclopentane polyhydrogen phenanthrene nucleus structure and is an important steroid compound in mammals. It not only participates in the formation of cell membranes, but is also an important substance for the synthesis of steroid hormones. The combination of phospholipid bilayers and cholesterol in a certain proportion can form liposomes, also known as lipid microcapsules. They are composed of a single amphiphilic bilayer encapsulating one and / or multiple amphiphilic bilayers separating a series of concentric discontinuous aqueous compartments. They have an artificial membrane structure with fluidity similar to that of a cell membrane. The phospholipid bilayer serves as the skeleton of the membrane, and cholesterol has a high melting point and can regulate the phase transition temperature and fluidity of the membrane. Water-soluble drugs are often contained in the aqueous compartment, while lipophilic drugs are contained in the lipid bilayer of the liposome.

[0007] Steroid hormones, also known as steroid hormones, have a cyclopentahydrophenanthrene nucleus and can be divided into adrenal cortical hormones and sex hormones based on their pharmacological effects. Adrenal cortical hormones include corticosterone, 11-dehydrocorticosterone, hydrocortisone, and cortisone, which regulate glucose metabolism and have excellent anti-inflammatory and anti-allergic effects, also known as steroidal anti-inflammatory drugs; as well as 11-deoxycorticosterone, 17-hydroxy-11-deoxycorticosterone, and aldosterone, which regulate water and salt metabolism.

[0008] Sex hormones include androgens and estrogens and progestogens. Androgens include methyltestosterone, testosterone propionate, and testosterone undecanoate; estrogens and progestogens include progesterone, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, chlormadinone acetate, estradiol, estrone, estriol, ethinylestradiol, estradiol benzoate, estradiol valerate, ethinylestradiol, tibolone, dienogest, and dydrogesterone acetate. Steroid hormones are widely used clinically, but many unmet clinical needs remain. For example, the steroidal progestogen progesterone, progesterone, exhibits low solubility and permeability, poor water solubility, and low oral bioavailability. Clinically, progesterone is dissolved in injectable vegetable oils such as castor oil and soybean oil to form an oily solution. A single dose can maintain efficacy for one day, but oily injections are difficult to absorb and can cause local muscle inflammation and severe pain. Frequent daily injections can lead to significant peaks and troughs in blood concentrations, numerous adverse reactions, and low patient compliance.

[0009] Summary of the Invention

[0010] To solve the above technical problems, in a first aspect, the present invention provides a pharmaceutical composition comprising steroid hormones and phospholipids.

[0011] According to an embodiment of the present invention, the steroid hormone is one or more of adrenal hormones and sex hormones, preferably, selected from sex hormones. Preferably, the sex hormone is selected from one or more of progesterone, estradiol, dienogest, dydrogesterone, tibolone, testosterone undecanoate, etc.

[0012] According to an embodiment of the present invention, the phospholipid includes a natural or synthetic phospholipid, which has a structural feature of having a hydrophilic head composed of a substituted group (including an amine base or an alcohol) connected to a phosphate and a hydrophobic tail composed of a fatty acid chain. In some embodiments, the phospholipid is selected from one or more of glycerophospholipids and sphingomyelin, and the glycerophospholipid is selected from one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and glycerophosphatidic acid. Examples of phospholipids suitable for use in the present invention include one or more of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dierucoylphosphatidylcholine, egg yolk phosphatidylcholine, dilauroylphosphatidylcholine, hydrogenated soybean phosphatidylcholine, 1-stearoyl-2-palmitoylphosphatidylcholine, distearoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dipalmitoylphosphatidylserine, dimyristoylphosphatidylserine, and distearoylphosphatidylserine; preferably, the phospholipid is selected from dimyristoylphosphatidylcholine.

[0013] According to an embodiment of the present invention, the molar ratio of the phospholipid to the steroid hormone is 1:1000-1000:1, preferably 1:100-100:1, more preferably 10:1 to 1:10, for example 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10.

[0014] According to an embodiment of the present invention, the pharmaceutical composition may further comprise cholesterol.

[0015] According to an embodiment of the present invention, the molar ratio of phospholipid to cholesterol is 10:1 to 1:10, for example, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, preferably, 4:1 to 1:1.

[0016] According to an embodiment of the present invention, the pharmaceutical composition may further comprise a solvent, wherein the solvent is selected from one or a combination of organic solvents and / or water. Preferably, the organic solvent is selected from protic solvents, such as alcohols.

[0017] According to an embodiment of the present invention, the protic solvent is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, benzyl alcohol, formic acid, and acetic acid.

[0018] According to an embodiment of the present invention, the alcohol is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, and benzyl alcohol.

[0019] In some embodiments, the solvent is selected from a mixed solution of a protic solvent and water (i.e., an aqueous solution of a protic solvent). Preferably, the solvent is an aqueous solution of tert-butanol; preferably, the content of the protic solvent in the aqueous solution of the protic solvent is ≥50% (v / v), for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% (v / v). More preferably, the content of the protic solvent in the aqueous solution of the protic solvent is ≥60% (v / v).

[0020] According to an embodiment of the present invention, the mass volume ratio of the steroid hormone to the solvent is 30-100 g / L, for example, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 g / L.

[0021] According to an embodiment of the present invention, the composition comprises 10-100 parts of the steroid hormone, preferably 10-70 parts of the steroid hormone, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60 , 65, 70, 75, 80, 85, 90, 95, 100 parts; the composition comprises 5-300 parts of the phospholipid in parts by weight, for example, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 parts.

[0022] According to an embodiment of the present invention, when the composition further comprises cholesterol, it comprises 1-50 parts by weight of cholesterol, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50 parts.

[0023] In some embodiments, the pharmaceutical composition comprises progesterone, cholesterol and phospholipids, the phospholipids are selected from DMPC, and the molar ratio of the phospholipids to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, and the content of tert-butanol in the tert-butanol aqueous solution is ≥60% (v / v).

[0024] In some embodiments, the pharmaceutical composition comprises, by weight, 10-70 parts of progesterone; 1-30 parts of cholesterol; and 8-100 parts of phospholipids.

[0025] In some embodiments, the pharmaceutical composition comprises estradiol, cholesterol and phospholipid, the phospholipid is selected from DMPC, and the molar ratio of the phospholipid to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, and the content of tert-butanol in the tert-butanol aqueous solution is ≥60% (v / v).

[0026] In some embodiments, the pharmaceutical composition comprises, by weight, 10-70 parts of estradiol; 1-30 parts of cholesterol; and 8-100 parts of phospholipid.

[0027] In some embodiments, the pharmaceutical composition comprises dienogest, cholesterol and phospholipid, the phospholipid is selected from DMPC, and the molar ratio of the phospholipid to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, and the content of tert-butanol in the tert-butanol aqueous solution is ≥60% (v / v).

[0028] In some embodiments, the pharmaceutical composition comprises, by weight, 10-70 parts of dienogest; 1-50 parts of cholesterol; and 30-150 parts of phospholipid.

[0029] In some embodiments, the composition is a solid composition, which may be a lyophilized powder. In some embodiments, the present invention provides a solid composition obtained by mixing the steroid hormone, phospholipid, and solvent and then drying. In other embodiments, the present invention provides a solid composition obtained by mixing the steroid hormone, cholesterol, phospholipid, and solvent and then drying.

[0030] According to an embodiment of the present invention, the drying comprises air drying, rotary evaporation, freeze drying, spray drying or freeze spray drying, preferably freeze drying.

[0031] According to an embodiment of the present invention, the solid composition can be reconstituted using one or more sterile aqueous solvents such as water for injection, physiological saline, PBS buffer, amino acid buffer, etc.

[0032] In another aspect, the present invention provides a method for preparing the composition, comprising the steps of:

[0033] (i) mixing the steroid hormone, phospholipid, and optionally added cholesterol with a solvent to obtain a solution;

[0034] In some embodiments, in step (i), the steroid hormone, phospholipid and solvent are mixed to obtain a solution; in some embodiments, in step (i), the steroid hormone, phospholipid and cholesterol are mixed to obtain a solution; preferably, the steroid hormone and cholesterol can be dissolved in the solvent first, and then the phospholipid is added for dissolution; the steroid hormone and phospholipid can also be directly dissolved in the solvent; the steroid hormone, cholesterol and phospholipid can also be directly dissolved in the solvent; the mixing / dissolving process can be carried out under mixing conditions such as stirring, ultrasound, vortexing, etc., preferably with heating and stirring in a water bath; the mixing / dissolving can be carried out at a suitable temperature, for example, 10°C-100°C, preferably 20°C-85°C, more preferably 35-55°C; the stirring speed is 10rpm-20000rpm, preferably 100rpm-12000rpm.

[0035] The preparation method further comprises the following steps:

[0036] (ii) preparing the solution into a solid composition.

[0037] According to an embodiment of the present invention, in step (ii), the method for preparing the solid composition comprises air drying, rotary evaporation, freeze drying, spray drying or freeze spray drying, preferably freeze drying.

[0038] According to an embodiment of the present invention, during the freeze-drying process, the pre-freezing conditions preferably maintain a plate temperature of -20 to -50°C for a holding time of 10 to 360 minutes. The sublimation drying conditions preferably maintain a vacuum of 0.01 to 10 mbar, a plate temperature of -1 to -50°C, and a holding time of 30 to 1500 minutes. The desorption drying conditions preferably maintain a vacuum of 0.01 to 1 mbar, a plate temperature of 0 to 50°C, and a holding time of 30 to 1500 minutes.

[0039] According to an embodiment of the present invention, the solid composition prepared by the present invention can be reconstituted to obtain a liquid, wherein the reconstitution comprises: preparing the solid composition into a suspension in an aqueous dispersion medium. The aqueous dispersion medium is selected from one or more of water for injection, physiological saline, PBS buffer, amino acid buffer, etc.; the mass concentration of the suspension is 0.01g / ml-10g / ml; the pH range of the PBS or amino acid buffer is 5.5-8.5, preferably 6.0-8.0, and the mass concentration is 0.001M-10M, preferably 0.01M-1M.

[0040] In another aspect, the solid composition obtained by the preparation method of the present invention.

[0041] According to an embodiment of the present invention, the present invention further provides a preparation, which is obtained by redissolving the composition of the present invention (eg, the solid composition obtained according to the preparation method) in an aqueous dispersion medium.

[0042] According to an embodiment of the present invention, the particle size of the particles in the suspension obtained after the solid composition is re-dissolved is:

[0043] D 10 1-15 μm, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 μm;

[0044] D 50 5-50 μm; for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 μm.

[0045] D 9020-150μm, for example, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150μm.

[0046] According to an embodiment of the present invention, the preparation can be administered topically, preferably by subcutaneous injection and intramuscular injection.

[0047] According to an embodiment of the present invention, the preparation can release the active ingredient for a long time after administration. In some embodiments, the active ingredient release effect can be maintained in the body for 5-30 days (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 30 days). Beneficial effects

[0048] The present invention provides a steroid hormone phospholipid composition. The composition is prepared as a freeze-dried powder, is easy to store, has good stability, good safety, high solubility, and is easy to use. The reconstituted preparation can maintain a long-term stable release effect in the body for 5-30 days. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 shows the cryo-electron microscopy image of the blank control sample of the D-0 formulation reconstituted with normal saline

[0050] Figure 2 shows the cryo-electron microscopy image of the formula D-1 reconstituted with saline

[0051] Figure 3 shows the cryo-electron microscopy image of the formula D-2 reconstituted with normal saline

[0052] Figure 4 shows the cryo-electron microscopy image of the formula D-3 reconstituted with normal saline

[0053] Figure 5 shows the blood concentration curves of the long-acting progesterone phospholipid composition and the reference substance in rats in Example 1

[0054] Figure 6 shows the blood concentration curves of the long-acting progesterone phospholipid composition and the reference substance in rats in Example 2

[0055] Figure 7 shows the blood concentration curves of the long-acting estradiol phospholipid composition and the reference substance in rats in Example 3

[0056] Figure 8 shows the blood concentration curves of the long-acting dienogest phospholipid composition and the reference substance in rats in Example 4 DETAILED DESCRIPTION

[0057] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.

[0058] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0059] Abbreviation of substance name:

[0060] DMPC dimyristoylphosphatidylcholine

[0061] DOPC dioleoylphosphatidylcholine

[0062] DPPG dipalmitoylphosphatidylglycerol

[0063] HSPC Hydrogenated Soy Phosphatidylcholine

[0064] Preparation Example

[0065] Preparation Example 1. Preparation of long-acting progesterone phospholipid composition

[0066] Table 1

[0067] Preparation of solid composition:

[0068] Weigh 200g of progesterone and 92.4g of cholesterol, add 3L of 90% (v / v) tert-butyl alcohol, and stir at room temperature until dissolved to form a steroidal mixed solution. Add 324g of DMPC and stir at room temperature until dissolved. Dispense into 1000 10ml vials, 3.4ml per vial. Freeze-dry the sample in a freeze dryer to obtain the product.

[0069] Preparation of reconstituted material:

[0070] The above freeze-dried product was reconstituted with an appropriate amount of physiological saline and mixed evenly to form a uniform suspension, which appeared as an irregular circular flowable shape under a microscope.

[0071] Preparation Example 2. Preparation of long-acting progesterone phospholipid composition

[0072] Table 2

[0073] Preparation of solid composition:

[0074] Weigh 314.5g of progesterone, add 3L of 80% (v / v) tert-butyl alcohol, and stir at 65°C until dissolved to form a steroidal mixed solution. Add 6779g of DMPC and stir at 65°C until dissolved. Dispense into 1500 10ml vials, 2.3ml per vial. Freeze-dry the sample in a freeze dryer.

[0075] Preparation of reconstituted material:

[0076] The above freeze-dried product was reconstituted with an appropriate amount of physiological saline and mixed evenly to form a uniform suspension, which appeared as an irregular circular flowable shape under a microscope.

[0077] Preparation Example 3. Preparation of long-acting estradiol phospholipid composition

[0078] Table 3

[0079] Preparation of solid composition:

[0080] Weigh estradiol and cholesterol according to the prescribed amount, add 0.5L of 80% (v / v) tert-butanol, stir at room temperature until dissolved, weigh DMPC and add it, stir at room temperature until dissolved, and dispense into 1000 vials, 0.53ml per bottle. After aliquoting, freeze-dry to obtain the product.

[0081] Preparation of reconstituted material:

[0082] The above freeze-dried product was reconstituted with an appropriate amount of physiological saline and mixed evenly to form a uniform suspension, which appeared as an irregular circular flowable shape under a microscope.

[0083] Preparation Example 4. Preparation of long-acting dienogest phospholipid composition

[0084] Table 4

[0085] Preparation of solid composition:

[0086] Weigh 13.0 g of dienogest and 26.0 g of cholesterol, add 2.0 L of 80% (v / v) tert-butanol, stir at room temperature until dissolved to form a steroid mixed solution, add 91.0 g of DMPC, stir at room temperature until dissolved, and dispense into 1000 vials, 2.2 ml per vial, and then lyophilize to obtain the product.

[0087] Preparation of reconstituted material:

[0088] The above freeze-dried product was reconstituted with an appropriate amount of physiological saline and mixed evenly to form a uniform suspension, which appeared as an irregular circular flowable shape under a microscope.

[0089] Prescription research

[0090] (1) Phospholipid types

[0091] In order to investigate the drugability of different phospholipid excipients, the compositions of formulas 1-4 shown in Table A below were obtained by referring to the method of Preparation Example 1.

[0092] Table A

[0093] The results showed that in the mixed dissolution step of progesterone, phospholipids, cholesterol, and tert-butanol, DPPG (dipalmitoylphosphatidylglycerol) in recipe 2 could not form a solution, which would make the filtration and sterilization process in the production process impossible to implement. HSPC (hydrogenated soybean phosphatidylcholine) in recipe 3 still had a small amount of visible foreign matter after full dissolution, and a gel precipitated after standing at room temperature. DOPC (dioleoylphosphatidylcholine) in recipe 1 could produce a solid composition, but it agglomerated after redissolution and could not be evenly dispersed in the medium, affecting needle permeability. DMPC in recipe 4 formed a homogeneous solution in the dissolution step, remained clear and transparent after standing at room temperature for 24 hours, and was stable. The reconstituted progesterone phospholipid composition was visually observed as a homogeneous emulsion suspension with spherical particles and a multilayered cross-section. Therefore, DMPC is the preferred phospholipid excipient in the present invention.

[0094] (2) Solvent concentration

[0095] To investigate the effect of solvent concentration, compositions of formulations 5-10 as shown in Table B below were obtained by referring to the method of Preparation Example 1. The results are shown in the following table.

[0096] Table B

[0097] (3) Drug loading

[0098] As shown in Table C below, formulations C-1 to C-7 had increasing drug loadings ranging from 40% to 60%, with a DMPC:cholesterol ratio of 2:1 (molar ratio); formulations C-8 to C-14 had increasing drug loadings ranging from 40% to 60%, with a DMPC:cholesterol ratio of 3:1; formulations C-15 and C-16 were cholesterol-free. The particle size in the DMPC:cholesterol 2:1 group was significantly higher than that in the DMPC:cholesterol 3:1 group, with the cholesterol-free group exhibiting the smallest particle size. This suggests that DMPC, as the primary excipient, gives the progesterone phospholipid complex a multilayered structure, while cholesterol plays a modulating role in particle size. All of these formulations exhibit excellent drugability.

[0099] Table C

[0100] (4) Microstructure investigation

[0101] The effects of the formulations shown in Table D below on product morphology were investigated. Following the processes of Preparation Example 1 or Preparation Example 2, freeze-dried samples prepared according to the formulations in Table D below were reconstituted with physiological saline, and the microstructure of the reconstituted products was examined using cryo-electron microscopy. As can be seen from the cryo-electron micrographs in Figures 1-4, the resulting products all exhibited multilayer structures, meeting the requirements.

[0102] Table D

[0103] Effect Example 1

[0104] Pharmacokinetic study of progesterone phospholipid composition in rats

[0105] Test sample: Take a single long-acting progesterone phospholipid freeze-dried composition prepared according to Preparation Example 1, add appropriate amount of physiological saline to reconstitute and suspend it to prepare the test sample, with a specification of 67 mg / ml.

[0106] Reference substance: Commercially available progesterone injection, specification 1ml: 25mg (Mochida Pharmaceutical Co., Ltd., Japan)

[0107] Experimental animals: Sprague Dawley rats (SPF grade), male SD rats, aged 6-8 weeks, weighing 180-250 g, 6 rats per group, original source: Sprague Dawley (Beijing) Biotechnology Co., Ltd.; certificate number: 1103242201003859385; production license number: SCXK (Beijing) 2019-0010.

[0108] Test steps:

[0109] (1) Grouping and experimental design are detailed in Table E-1 below.

[0110] Table E-1

[0111] (2) Sample collection

[0112] Group 1: Subcutaneous injection, blood samples were collected at 0, 0.25h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, 120h, 144h, 216h, 264h, 312h, and 336h to measure the blood concentration of progesterone.

[0113] Group 2: intramuscular injection, blood samples were collected at 0, 0.25h, 0.5h, 1h, 2h, 4h, 8h, 12h, and 24h to measure the blood concentration of progesterone.

[0114] The collected blood samples were placed in heparinized blood collection tubes and centrifuged to separate the plasma (6800 g, 6 min, 2-8°C). The plasma samples were stored at -80°C until delivery. The drug concentration in the plasma was determined by HPLC-MS / MS.

[0115] Draw the blood drug concentration curve as shown in Figure 5.

[0116] Table E-2

[0117] As shown in Table E-2, after subcutaneous injection of the progesterone lecithin composition of the present invention into rats, the half-life of the lecithin composition was approximately 5.6 times that of the commercially available injection, demonstrating that the progesterone lecithin composition has an ideal sustained-release effect. The dosage of the lecithin composition was approximately 14 times that of the commercially available injection, but the peak concentration (Cmax) of the two was similar, demonstrating the good safety of the lecithin composition. The clinical single-dose dosage can reach at least 7 times that of the commercially available preparation. In summary, the rat PK data of the progesterone lecithin composition show that the product can both quickly take effect and maintain a sustained-release effect for a long time, and has good tolerability, which is conducive to improving patient compliance with medication.

[0118] Table E-3

[0119] As shown in Table E-3 and Figure 5, in rats, the progesterone phospholipid composition of the present invention has a slightly higher blood concentration Cmax than the commercially available injection. At the same time, the average blood concentration can be maintained for about 11 days, which is above the Cmin of the commercially available injection, proving that it can be released long-term for 11 days, thus helping to improve medication compliance.

[0120] Effect Example 2

[0121] According to the formulation shown in Table F-1 below, sample 1-5 was prepared using the same method as in Preparation Example 1.

[0122] Table F-1

[0123] (1) Reference substance: Commercially available progesterone injection, specification 1 ml: 25 mg (Mochida Pharmaceutical Co., Ltd., Japan)

[0124] (2) Experimental animals: Sprague Dawley rats (SPF grade), male SD rats, aged 6-8 weeks, weighing 180-250 g, 6 rats per group, original source: Sprague Dawley (Beijing) Biotechnology Co., Ltd.; certificate number: 1103242201003859385; production license number: SCXK (Beijing) 2019-0010.

[0125] (3) Test steps

[0126] The grouping and experimental design are shown in Table F-2 below.

[0127] Table F-2

[0128] Collect samples

[0129] Test group 1-5: subcutaneous injection, blood samples were collected at 0, 0.25h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h, 72h, 96h, 120h, 144h, and 168h to measure the blood concentration of progesterone;

[0130] Control group: intramuscular injection, blood samples were collected at 0, 0.25h, 0.5h, 1h, 2h, 4h, 8h, 12h, and 24h to measure the blood concentration of progesterone.

[0131] The collected blood samples were placed in heparinized blood collection tubes and centrifuged to separate the plasma (6800 g, 6 min, 2-8°C). The plasma samples were stored in a -80°C freezer until delivery. The drug concentration in the plasma was determined by HPLC-MS / MS, and the blood drug concentration curve was plotted as shown in Figure 6.

[0132] Table F-3

[0133] In the experiment of Effect Example 2, the dosage was administered for 7 days, and the average sustained-release time was more than 5 days. Combined with the experimental results of Effect Example 1, where the dosage was administered for 14 days and the average sustained-release time was 11 days, it can be seen that the effective concentration sustained-release time of the long-acting progesterone phospholipid composition ranges from 5 to 11 days, and its sustained-release effect is related to the dosage. It is estimated that if the dosage form is administered for 10 days, the average sustained-release time is 7 days.

[0134] Table F-4

[0135] Effect Example 3 Pharmacokinetic Study of Estradiol Phospholipid Composition in Rats

[0136] Test sample 1: A long-acting estradiol phospholipid freeze-dried composition was prepared according to prescription A in Preparation Example 3. A single tube was added with an appropriate amount of physiological saline for reconstitution and suspension to prepare the test sample, with a specification of 12 mg / ml.

[0137] Test sample 2: A long-acting estradiol phospholipid freeze-dried composition was prepared according to prescription B in Preparation Example 3. A single vial was added with an appropriate amount of physiological saline for reconstitution and suspension to prepare the test sample, with a specification of 12 mg / ml.

[0138] Reference substance: Commercially available estradiol tablets (Abbott Healthcare Products BV), 1 mg. The commercially available estradiol tablets were ground into a solid powder using a mortar and pestle. The powder was weighed and resuspended in an appropriate amount of physiological saline to prepare a reference solution at a concentration of 2 mg / ml.

[0139] Experimental animals: Sprague Dawley rats (SPF grade), male SD rats, aged 6-8 weeks, weighing 200-220 g, 6 rats per group, original source: Sprague Dawley (Beijing) Biotechnology Co., Ltd.; certificate number: 110324220107108468; production license number: SCXK (Beijing) 2019-0010.

[0140] Test steps:

[0141] (1) Grouping and experimental design are shown in Table G-1 below.

[0142] Table G-1

[0143] Note: The oral bioavailability of the reference substance is 5%

[0144] (2) Sample collection

[0145] Group 1: Subcutaneous injection, blood samples were collected at 0h (before administration) and 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, and 168h after administration to measure the blood concentration of estradiol.

[0146] Group 2: Subcutaneous injection, blood samples were collected at 0h (before administration) and 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, and 168h after administration to measure the blood concentration of estradiol.

[0147] Group 3: Oral gavage, blood samples were collected at 0h (before administration) and 0.5h, 1h, 2h, 4h, 6h, 8h, and 24h after administration to measure the blood concentration of estradiol.

[0148] The collected blood samples were placed in heparinized blood collection tubes and centrifuged to separate the plasma (4000 rpm, 10 min, 2-8°C). The plasma samples were stored in a -40°C freezer until delivery. The drug concentration in the plasma was determined by HPLC-MS / MS.

[0149] Table G-2

[0150] Table G-3

[0151] The pharmacokinetic parameters and drug-dose curves of the estradiol phospholipid composition test samples 1 and 2 of the present invention, following a single subcutaneous injection in rats, are shown in Tables G-2 and G-3 and Figure 7. Similar sustained-release effects were observed across the excipient molar ratio of DMPC to cholesterol of 1:1 to 2:1. The half-life of the phospholipid composition was extended to approximately 12 times that of commercially available tablets. Estradiol phospholipid composition test samples 1 and 2 exhibited sustained release for at least 7 days after a single dose. The rat PK data for the estradiol phospholipid composition demonstrate that the product exhibits both rapid onset of action and sustained, stable, sustained release over an extended period, demonstrating its development potential.

[0152] Effect Example 4

[0153] Pharmacokinetic study of dienogest phospholipid composition in rats

[0154] Test sample: Take a single vial of the long-acting dienogest phospholipid freeze-dried composition prepared according to Preparation Example 4, add an appropriate amount of physiological saline to reconstitute and suspend it to prepare a test sample with a specification of 13 mg / ml.

[0155] Reference substance: Commercially available dienogest tablets, strength: 2 mg (Bayer Weimar GmbH and Co.KG). The commercially available dienogest tablets were crushed into solid powder using a mortar and pestle, weighed, and then reconstituted and suspended in an appropriate amount of physiological saline to prepare a reference substance solution with a concentration of 1 mg / ml.

[0156] Experimental animals: Sprague Dawley rats (SPF grade), female SD rats, aged 6-8 weeks, weighing 180-250 g, 6 rats per group, original source: Sprague Dawley (Beijing) Biotechnology Co., Ltd.; certificate number: 110324230103521638; production license number: SCXK (Beijing) 2019-0010.

[0157] Test steps:

[0158] (1) Grouping and experimental design are detailed in Table H-1 below.

[0159] Table H-1

[0160] Note: The oral bioavailability of the control drug is 90%

[0161] (2) Sample collection

[0162] Group 1: Subcutaneous injection, blood samples were collected at 0h, 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 72h, and 168h to measure the blood concentration of dienogest.

[0163] Group 2: Oral gavage, blood samples were collected at 0h, 0.5h, 1h, 2h, 4h, 6h, 8h, and 24h (blood sampling time window ± 1 minute) to measure the blood concentration of dienogest.

[0164] Collected blood samples were placed in EP tubes and stored upright at 2-8°C. After centrifugation (4000 rpm, 2-8°C, 10 min), plasma was collected and divided into two 100 μL aliquots plus a backup. Plasma samples were stored at -80°C until delivery. Drug concentrations in plasma were determined by HPLC-MS / MS.

[0165] Table H-2

[0166] Table H-3

[0167] The results, as shown in Tables H-2, H-3, and Figure 8, show that after subcutaneous injection of the dienogest phospholipid composition of the present invention into rats, the half-life of the phospholipid composition was approximately 4.5 times that of a commercially available injection, demonstrating that the dienogest phospholipid composition has an ideal sustained-release effect. The peak concentration (Cmax) of the phospholipid composition was approximately 1 / 6 that of a commercially available tablet, demonstrating the good safety of the phospholipid composition. In summary, the rat PK data of the dienogest phospholipid composition demonstrate that the product has both a rapid onset of action and a long-term sustained-release effect, and is well tolerated, which is beneficial for improving patient compliance.

[0168] The above is an exemplary description of the implementation methods of the technical solution of the present invention. It should be understood that the scope of protection of the present invention is not limited to the above implementation methods. Any modifications, equivalent substitutions, improvements, etc. made by those skilled in the art within the spirit and principles of the present invention shall be included in the scope of protection of the claims of this application.

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises steroid hormones and phospholipids, wherein the steroid hormones are one or more of adrenal hormones and sex hormones; and the phospholipids include natural or synthetic phospholipids.

2. The pharmaceutical composition according to claim 1, characterized in that The sex hormone is selected from one or more of progesterone, estradiol, dienogest, dydrogesterone, tibolone, testosterone undecanoate, etc.; The phospholipid is selected from one or more of glycerophospholipids and sphingomyelins, and the glycerophospholipid is selected from one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and glycerophosphatidic acid; the phospholipid is, for example, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dierucoylphosphatidylcholine, egg yolk phosphatidylcholine, dilauroylphosphatidylcholine. One or more of alkali, hydrogenated soy phosphatidylcholine, 1-stearoyl-2-palmitoylphosphatidylcholine, distearoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dipalmitoylphosphatidylserine, dimyristoylphosphatidylserine, and distearoylphosphatidylserine; preferably, the phospholipid is selected from dimyristoylphosphatidylcholine.

3. The pharmaceutical composition according to claim 1 or 2, characterized in that The molar ratio of the phospholipid to the steroid hormone is 1:1000-1000:1, preferably 1:100-100:1, more preferably 10:1 to 1:10, for example 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:

10.

4. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that The pharmaceutical composition further comprises cholesterol; preferably, the molar ratio of the phospholipid to cholesterol is 10:1 to 1:10, for example, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, more preferably, 4:1 to 1:

1.

5. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that The pharmaceutical composition further comprises a solvent, wherein the solvent is selected from one or a combination of organic solvents and / or water, preferably, the organic solvent is selected from protic solvents, such as alcohols; Preferably, the protic solvent is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, benzyl alcohol, formic acid, and acetic acid; Preferably, the alcohol is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, and benzyl alcohol; Preferably, the solvent is selected from a mixed solution of a protic solvent and water (i.e., an aqueous solution of a protic solvent). Preferably, the solvent is an aqueous solution of tert-butanol; preferably, the content of the protic solvent in the aqueous solution of the protic solvent is ≥50% (v / v), more preferably, the content of the protic solvent in the aqueous solution of the protic solvent is ≥60% (v / v); Preferably, the mass volume ratio of the steroid hormone to the solvent is 30-100 g / L.

6. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that The composition comprises 10-100 parts of the steroid hormone, preferably 10-70 parts of the steroid hormone, in parts by weight; the composition comprises 5-300 parts of the phospholipid, in parts by weight; and when the composition further comprises cholesterol, the composition comprises 1-50 parts of cholesterol, in parts by weight; Preferably, the pharmaceutical composition comprises progesterone, cholesterol and phospholipid, wherein the phospholipid is selected from DMPC, and the molar ratio of the phospholipid to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, wherein the tert-butanol content in the tert-butanol aqueous solution is ≥60% (v / v); Preferably, the pharmaceutical composition comprises, by weight, 10-70 parts of progesterone; 1-30 parts of cholesterol; and 8-100 parts of phospholipids. Preferably, the pharmaceutical composition comprises estradiol, cholesterol and phospholipid, wherein the phospholipid is selected from DMPC, and the molar ratio of the phospholipid to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, wherein the tert-butanol content in the tert-butanol aqueous solution is ≥60% (v / v); Preferably, the pharmaceutical composition comprises, by weight, 10-70 parts of estradiol; 1-30 parts of cholesterol; 8-100 parts of phospholipids; Preferably, the pharmaceutical composition comprises dienogest, cholesterol and phospholipid, wherein the phospholipid is selected from DMPC, and the molar ratio of the phospholipid to cholesterol is 5:1 to 1:1; preferably, the pharmaceutical composition further comprises tert-butanol or a tert-butanol aqueous solution, wherein the tert-butanol content in the tert-butanol aqueous solution is ≥60% (v / v); Preferably, the pharmaceutical composition comprises, by weight, 10-70 parts of dienogest; 1-50 parts of cholesterol; and 30-150 parts of phospholipid.

7. The method for preparing the pharmaceutical composition according to any one of claims 1 to 6, characterized in that The steps include: (i) mixing the steroid hormone, phospholipid, optionally added cholesterol and a solvent to obtain a solution.

8. The preparation method according to claim 7, characterized in that The mixing process can be carried out under stirring, ultrasonic, vortex and other mixing conditions, preferably water bath heating and stirring; the mixing / dissolving can be carried out at a suitable temperature, for example, 10°C-100°C, preferably 20°C-85°C, more preferably 35-55°C; the stirring speed is 10rpm-20000rpm, preferably 100rpm-12000rpm.

9. The preparation method according to claim 7 or 8, characterized in that The preparation method further comprises the following steps: (ii) preparing the solution into a solid composition; Preferably, in step (ii), the method for preparing the solid composition includes air drying, rotary evaporation, freeze drying, spray drying or freeze spray drying, preferably freeze drying.

10. A preparation, obtained by reconstituted in an aqueous dispersion medium the pharmaceutical composition according to any one of claims 1 to 6 or the pharmaceutical composition obtained by the preparation method according to any one of claims 7 to 9; preferably, the preparation can be administered topically, more preferably, by subcutaneous injection and intramuscular injection.